Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1/2 6Phase 3 3Phase 1 2Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Prostatic Neoplasms 1Gliosarcoma 1Glioblastoma 1

Interventions

Specimen Handling 98Biopsy 69Magnetic Resonance Spectroscopy 63pembrolizumab 46Cyclophosphamide 43fludarabine 38Carboplatin 22venetoclax 19Nivolumab 18Cetuximab 18Bevacizumab 17Radiotherapy 16fludarabine phosphate 15Cisplatin 15X-Rays 14Ipilimumab 13Fluorouracil 13Cytarabine 13Temozolomide 12Leucovorin 12Irinotecan 12atezolizumab 11Radiation 11Paclitaxel 11Azacitidine 11durvalumab 10Oxaliplatin 10Injections 10Gemcitabine 10Dexamethasone 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × cemiplimab × 30 days × Clear all
NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT06826768 2026-05-08

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

M.D. Anderson Cancer Center

Phase 1 Recruiting
60 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡